CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,325.08% | 1,041.37% | 68.55% | -97.58% | 47.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,325.08% | 1,041.37% | 68.55% | -97.58% | 47.67% |
| Cost of Revenue | -2.45% | -6.63% | -11.90% | 67.04% | 24.33% |
| Gross Profit | 12.70% | 14.81% | 12.44% | -193.49% | -24.18% |
| SG&A Expenses | 5.53% | -7.21% | -10.95% | 1.52% | -2.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.44% | -6.71% | -11.78% | 55.20% | 20.06% |
| Operating Income | 10.37% | 13.73% | 12.25% | -139.62% | -19.91% |
| Income Before Tax | -5.24% | 56.48% | 9.49% | -255.08% | -24.40% |
| Income Tax Expenses | -88.05% | -25.70% | -24.35% | -12.29% | -29.34% |
| Earnings from Continuing Operations | -4.69% | 56.29% | 9.61% | -250.07% | -23.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.69% | 56.29% | 9.61% | -250.07% | -23.85% |
| EBIT | 10.37% | 13.73% | 12.25% | -139.62% | -19.91% |
| EBITDA | 10.57% | 13.94% | 12.36% | -149.56% | -21.10% |
| EPS Basic | 1.19% | 60.57% | 19.13% | -214.02% | -15.62% |
| Normalized Basic EPS | 11.10% | 28.70% | 19.02% | -218.57% | -16.13% |
| EPS Diluted | 1.55% | 60.65% | 19.12% | -214.04% | -15.84% |
| Normalized Diluted EPS | 11.10% | 28.70% | 19.02% | -218.57% | -16.13% |
| Average Basic Shares Outstanding | 5.95% | 10.85% | 11.77% | 11.47% | 7.12% |
| Average Diluted Shares Outstanding | 5.95% | 10.85% | 11.77% | 11.47% | 7.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |